Literature DB >> 7639058

Serum and urinary manganese levels in patients with Parkinson's disease.

F J Jiménez-Jiménez1, J A Molina, M V Aguilar, F J Arrieta, A Jorge-Santamaría, F Cabrera-Valdivia, L Ayuso-Peralta, M Rabasa, A Vázquez, E García-Albea.   

Abstract

To elucidate the possible role of manganese in the risk of developing Parkinson's disease (PD), we compared serum levels of manganese, and 24-h manganese excretion by urine in 29 PD patients and in 27 matched controls. We also measured chromium and cobalt in the same samples. All these values did not differ significantly between the groups, they were not influenced by antiparkinsonian drugs, and they did not correlate with age, age at onset and duration of the PD, scores of the Unified PD Rating Scale or the Hoehn & Yahr staging in the PD group. These results might suggest that serum levels and urinary excretion of manganese are apparently unrelated to the risk of developing PD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639058     DOI: 10.1111/j.1600-0404.1995.tb07014.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  2 in total

1.  Parkinson's disease and other basal ganglia or movement disorders in a large nationwide cohort of Swedish welders.

Authors:  C M Fored; J P Fryzek; L Brandt; G Nise; B Sjögren; J K McLaughlin; W J Blot; A Ekbom
Journal:  Occup Environ Med       Date:  2006-02       Impact factor: 4.402

2.  Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.

Authors:  P A Serra; G Esposito; P Enrico; M A Mura; R Migheli; M R Delogu; M Miele; M S Desole; G Grella; E Miele
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.